Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Buy" by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

A number of brokerages have recently issued reports on PYXS. Stifel Nicolaus began coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a "buy" rating and a $10.00 price objective for the company. Royal Bank of Canada restated an "outperform" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th.

Pyxis Oncology Stock Performance

Shares of PYXS traded up $0.14 during mid-day trading on Thursday, reaching $3.75. 512,365 shares of the company were exchanged, compared to its average volume of 632,784. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The stock has a market capitalization of $222.83 million, a PE ratio of -3.04 and a beta of 1.27. The business has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $3.74.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. On average, analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the company. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the second quarter valued at approximately $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology during the first quarter valued at approximately $59,000. The Manufacturers Life Insurance Company purchased a new position in shares of Pyxis Oncology during the second quarter valued at approximately $65,000. Cetera Advisors LLC purchased a new position in shares of Pyxis Oncology during the first quarter valued at approximately $100,000. Finally, Schulhoff & Co. Inc. boosted its position in shares of Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company's stock valued at $139,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.